BioAtla, Inc.

Equities

BCAB

US09077B1044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-27 pm EDT			5-day change	1st Jan Change
1.47 ^USD	+4.26%		+3.89%	-40.24%

May. 23	BioAtla, Inc. Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology Annual Meeting	CI
May. 15	Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Ahead of Key Inflation, Retail Data	MT

BioAtla, LLC announced that it expects to receive $15 million in funding from Biotech Investment Group.

January 09, 2016

BioAtla, LLC announced that it will receive $15 million in an equity round of funding from new investor Global BIO Impact Fund, a fund managed by Biotech Investment Group on January 10, 2016. The transaction is expected to completed by the end of January 2016.

Latest news about BioAtla, Inc.

BioAtla, Inc. Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology Annual Meeting	May. 23	CI
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Ahead of Key Inflation, Retail Data	May. 15	MT
BioAtla Shares Jump 10% in Premarket Activity Wednesday as Diluted Net Loss Narrows in Q1	May. 15	MT
Transcript : BioAtla, Inc., Q1 2024 Earnings Call, May 14, 2024	May. 14
BioAtla, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
BioAtla's Multiple Cancer Drug Candidate Receives FDA Clearance	May. 06	MT
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors	May. 06	CI
HC Wainwright Adjusts BioAtla's Price Target to $7 From $10, Maintains Buy Rating	Mar. 27	MT
Transcript : BioAtla, Inc., Q4 2023 Earnings Call, Mar 26, 2024	Mar. 26
BioAtla, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Transcript : BioAtla, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 09:45 AM	Jan. 11
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	Dec. 21	MT
Sector Update: Health Care Stocks Advance in Afternoon Trading	Dec. 21	MT
BioAtla Rallies After CEO Buys 50,000 Shares	Dec. 21	MT
Transcript : BioAtla, Inc. - Special Call	Dec. 17
BioAtla, Inc.(NasdaqGM:BCAB) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Transcript : BioAtla, Inc. - Special Call	Dec. 13
Bioatla Hosting Virtual R&D Day to Highlight Ba3071 Cab-Ctla-4 Phase 1 Data in Multiple Solid Tumor Types	Dec. 13	CI
Sector Update: Health Care Stocks Slipping Tuesday Afternoon	Dec. 05	MT
BioAtla Says Clinical Benefits, Safety Profile Support Further Evaluation of Potential Lung Cancer Therapy	Dec. 05	MT
BioAtla, Inc. Presents Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event	Dec. 05	CI
Top Premarket Decliners	Nov. 27	MT
HC Wainwright Lowers Price Target on BioAtla to $10 From $17, Maintains Buy Rating	Nov. 08	MT
BioAtla, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Transcript : BioAtla, Inc., Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07

Chart BioAtla, Inc.

Duration

Period

More charts

Company Profile

BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Companyâs product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), BA3071, and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer (NSCLC). BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.47 USD

Average target price

10.67 USD

Spread / Average Target

+625.62%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIOATLA, INC.	-40.24%	67.84M
MODERNA, INC.	+21.85%	46.93B
LONZA GROUP AG	+37.63%	39.08B
IQVIA HOLDINGS INC.	-8.05%	38.48B
ALNYLAM PHARMACEUTICALS, INC.	+29.04%	31.01B
CELLTRION, INC.	-13.75%	26.14B
ICON PUBLIC LIMITED COMPANY	+10.65%	25.88B
MEDPACE HOLDINGS, INC.	+38.43%	12.53B
BIO-TECHNE CORPORATION	-6.92%	11.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.29%	10.65B

Other Biotechnology & Medical Research